Inhibrx director granted 10,000 options at $95.22

Amended Form 4 for Inhibrx Biosciences corrects director stock option grant to 10,000 options at a $95.22 exercise price, vesting in 2027.

This filing corrects an earlier one, and you can read the original Form 4 if you want to see what changed.

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. (INBX) reports that director Jon Faiz Kayyem received a corrected grant of 10,000 stock options on June 3, 2026, at an exercise price of $95.22 per share. These options become fully exercisable on June 3, 2027, and expire on June 3, 2036, with 10,000 options held directly after the grant. The amended Form 4 restates a prior filing to correct the number of options granted, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Kayyem Jon Faiz

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	10,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 10,000 contracts (Direct)

Footnotes (1)

1. F1. This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Key Figures

Stock options granted: 10,000 options Exercise price: $95.22 per share Options exercisable date: June 3, 2027 +2 more

5 metrics

Stock options granted 10,000 options Grant to director on June 3, 2026

Exercise price $95.22 per share Exercise price of stock option grant

Options exercisable date June 3, 2027 Date options become fully exercisable, subject to continued service

Expiration date June 3, 2036 Expiration of stock options granted

Options held after transaction 10,000 options Total stock options held directly following the grant

Key Terms

Stock Option (right to buy), exercise price, fully exercisable, expiration date

4 terms

Stock Option (right to buy) financial

"The security reported is a Stock Option (right to buy) common stock"

exercise price financial

"The options have an exercise price of 95.2200 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

fully exercisable financial

"This stock option will be fully exercisable on June 3, 2027"

expiration date financial

"The option carries an expiration date of June 3, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did INBX report in this amended Form 4?

INBX reported that director Jon Faiz Kayyem received a grant of 10,000 stock options on June 3, 2026, as a compensation-related acquisition of derivative securities.

What is the exercise price of the stock options granted to the INBX director?

The stock options granted to the INBX director have an exercise price of $95.22 per share, meaning they can be used to buy common stock at that price once exercisable.

When do the INBX stock options for Jon Faiz Kayyem vest and expire?

The stock options for Jon Faiz Kayyem become fully exercisable on June 3, 2027, subject to continued service through that date, and expire on June 3, 2036.

How many INBX options does the director hold after this transaction?

After this transaction, the director holds 10,000 stock options directly, each exercisable for one share of Inhibrx Biosciences common stock, according to the filing.

Why did Inhibrx Biosciences file an amended Form 4 for INBX?

The amended Form 4 was filed to correct the number of options granted to the reporting person, restating the original June 4, 2026 Form 4 due to an administrative error.

Were the INBX option transactions made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with this stock option grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 04:21 PM Accepted by SEC EDGAR 09/18/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kayyem Jon Faiz

(Last) (First) (Middle)

C/O INHIBRX BIOSCIENCES, INC.

11025 NORTH TORREY PINES ROAD, SUITE 140

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibrx Biosciences, Inc. [ INBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/04/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$95.22	06/03/2026		A		10,000		06/03/2027(1)	06/03/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Remarks:

This Amended Form 4 restates the original Form 4 filed on June 4, 2026 in its entirety to correct the number of options granted to the Reporting Person due to an administrative error.

	/s/ Kelly Deck, as attorney-in-fact to Jon Faiz Kayyem	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)